TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in a global phase 2 trial evaluating the efficacy and safety of DS-7300 ...
Daiichi Sankyo Company, Limited and Sarah Cannon Research Institute (SCRI), announced that the first patient has been dosed in a first-in-human phase 1/2 study evaluating DS-7300, an investigational ...
New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi Sankyo Company, Limited and Sarah Cannon Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results